Latest from The US Oncology Network

Practice with largest infusion treatment center in Delaware gains access to world-class treatments and enhances its cutting-edge research program.
Joyce A. O’Shaughnessy, MD, addresses the key issues in breast cancer discussed at the 2017 OncLive® State of the Science Summit on Treatment of Metastatic Breast Cancer and shared her expert insight on where triple-negative breast cancer treatment is headed based on recent findings.
Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses why the Syk inhibitor entospletinib demonstrates efficacy in patients with mantle cell lymphoma (MCL).
Keeping a medical practice strong and independent in today’s turbulent environment can be quite challenging.
Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses the mechanism of action with entospletinib (GS-9973) and its potential as a treatment for patients with mantle cell lymphoma (MCL).
New program automates and simplifies processes needed to successfully participate in the Oncology Care Model.
Christopher A. Yasenchak, MD, associate chair of Hematology Research, Willamette Valley Cancer Institute and Research Center/US Oncology Research, discusses results of a study examining the addition of brentuximab vedotin to R-CHOP for the treatment of patients with diffuse large B-cell lymphoma.
Pathways are effective tools for reducing unnecessary variability in care, a key factor in achieving better outcomes and more predictable costs.
Publication Bottom Border
Border Publication